Interleukin-2 before and/or after autologous bone marrow transplantation for pediatric acute leukemia patients

Bone Marrow Transplantation

Volumn 17, Issue 5, 1996, Pages 729-735

  Messina, C ^a,c   Zambello, R ^a   Rossetti, F ^a   Gazzola, M V ^a   Varotto, S ^a   Destro, R ^a   Basso, G ^b   Semenzato, G ^a   Zanesco, L ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c Centro Leucemie Infantili   (Italy)

Author keywords

Autologous BMT; Children; Immunotherapy; Interleukin 2

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; MELPHALAN; RECOMBINANT INTERLEUKIN 2; VINCRISTINE;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DIARRHEA; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; HUMAN CELL; HYPOTENSION; IMMUNOMODULATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOKINE ACTIVATED KILLER CELL; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; RASH; SCHOOL CHILD;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; RECOMBINANT PROTEINS; TRANSPLANTATION, AUTOLOGOUS;

EID: 0029976796     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Dinsmore R, Kirkpatrick D, Flomenberg N et al. Allogeneic bone marrow, transplantation for patients with acute lymphoblastic leukemia. Blood 1983; 91: 381-388.
2. Sanders JE, Thomas ED. and the Seattle Marrow Transplant Group. Marrow transplantation for children with acute non-lymphocytic leukemia in first remission. Med Pediatr Oncol 1981; 9: 423-427.
3. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
4. Lotzova E. The role of natural killer cells in immune surveillance against malignancies. Cancer Bull 1984; 36: 215-220.
5. Foà R, Fierro MT, Cesano A et al. Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease. Blood 1991; 78: 1041-1046.
6. Van Lochem E, De Gast B, Goulmy E. In vitro separation of host specific graft-versus-host and graft-versus-leukemia cytotoxic T cell activities. Bone Marrow Transplant 1992; 10: 181-183.
7. Faber LM, Van Luxembourg-Heijs SA, Willemze R et al. Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia. J Exp Med 1992; 176: 1283-1289.
8. Sallan SE, Neimeyer CM, Billet E et al. Autologous bone marrow transplantation for acute lymphoblastic leukemia. J Clin Oncol 1989; 7: 1594-1601.
9. Billet E, Kormehl B, Tarbell NJ et al. Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia. Blood 1993; 81: 1651-1657.
10. Kersey D, Weisdorf ME, Nesbit ME et al. Comparison of autologous and allogenic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. New Engl J Med 1987; 317: 461-466.
11. Gale RP, Butturini A, Reizenstein P. Autotransplant in leukemia: current states, future progress. Leukemia Res 1991; 15: 781-784.
12. Mallon K, Brenner MK, Rill DR. Gene marking to trace origin of relapse after autologous bone marrow transplantation. Lancet 1993; 341: 85-86.
13. Heslop HE, Gottlieb DJ, Reittle JE et al. Spontaneous and interleukin-2-induced secretion of tumor necrosis factor and gamma-interferon following autologous marrow transplantation or chemotherapy. Br J Haematol 1989; 72: 122-126.
14. Weite K, Keever C, Levick J et al. Interleukin-2 production and response to interleukin-2 by peripheral blood mononuclear cells from patients after bone marrow transplantation: II. Patients receiving soybean lectin-separated and T cell-depleted bone marrow. Blood 1987; 70: 1595-1603.
15. Velardi A. Varese P et al. Lymphokine production by T cell clones after human bone marrow transplantation. Blood 1989; 74: 1665-1672.
16. Heslop H et al. In vivo induction of gamma IFN and TNF by IL-2 infusion post-intensive CT or autologus BMT. Blood 1989; 74: 1374-1380.
17. Soiffer R, Murray C. Cochran K et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 autologous and T cell-depleted allogeneic bone marrow transplantation. Blood 1992; 79: 517-526.
18. Launa F, Raspadori D, Rondelli D et al. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer effectors: correlation with the rate and duration of complete remission and with survival. Leukemia 1994; 8: 724-728.
19. Allavena P, Damia G, Colombo T et al. Lymphokine-activated killer (LAK) and monocyte-mediated cytotoxicity on tumor cell lines resistant to antitumor agents. Cell Immunol 1989; 120: 250-258.
20. Klingemann HG, Eaves CJ, Barnett MJ et al. Transplantation of patients with high risk acute myeloid leukemia in first remission with autologous marrow cultured in interleukin-2 followed by interleukin-2 administration. Bone Marrow Transplant 1994; 14: 389-396.
21. Weisdorf DJ, Anderson PM, Blazar BR et al. Interleukin-2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia. A phase 1 study. Transplantation 1993; 55: 61-66.
22. Zambello R, Trentin L, Bulian P et al. Role of tumor necrosis factor (TNF)-alfa and its specific 75 and 55-kDa receptors in patients with lymphoproliferative disease of granular lymphocytes. Blood 1992; 80: 2030-2037.
23. Savary CA. Lotzova E. Inhibition of human bone marrow and myeloid progenitors by interleukin-2-activated lymphocytes. Exp Hematol 1990; 18: 1083-1089.
24. Baumgarten E, Schmid H. Pohl U et al. Low-dose natural interleukin-2 and recombinant interferon-gamma following autologous bone marrow grafts in pediatric patients with high-risk acute leukemia. Leukemia 1994; 8: 850-855.
25. Biaise D, Olive D, Stoppa AM et al. Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologus bone marrow transplantation. Blood 1990; 76: 1092-1097.
26. Higuchi CM, Thompson JA, Petersen FB et al. Toxicity and immunomodulatory effects of Interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991; 77: 2561-2568.
27. Meloni G, Foà R, Tosti A et al. Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study. Leukemia 1992; 6: 780-785.
28. Guarini A, Sanavio F. Novarino A et al. Thrombocytopenia in acute leukemia patients treated with IL-2: cytolytic effect of LAK cells on megakaryocytic progenitors. Br J Haematol 1991; 79: 451-456.
29. Heslop HE, Duncombe AS, Reittle JE et al. Interleukin-2 infusion induces haemopoietic growth factors and modifies marrow regeneration after chemotherapy or autologous marrow transplantation. Br J Haematol 1991; 77: 237-244.
30. Schaafsma MR, Falkenburg JHF, Landegent JE et al. In vivo production of interleukin-5 granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and interleukin-6 during intravenous administration of high-dose interleukin-2 in cancer patients. Blood 1991; 78: 1981-1987.
31. Murphy WJ, Keller JR, Harrison CL et al. Interleukin-2-activated natural killer cells can support hematopoiesis in vitro and promote marrow engraftment in vivo. Blood 1992; 80: 670-677.
32. Ellis TM, Creekmore SP, McMannis JD et al. Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin-2. Cancer Res 1988; 48: 6597-6608.
33. Weil-Hilman G, Fish P. Prieve AF et al. Lymphokine-activated killer activity induced by in vivo interleukin-2 therapy: predominant role for lymphocytes with increased expression of CD2 and Leu 19 antigens but negative expression of CD 16 antigen. Cancer Res 1989; 49: 3680-3688.
34. Trentin L, Pizzolo G, Feruglio C et al. Functional analysis of cytotoxic cells in patients with acute non-lymphoblastic leukemia in complete remission. Cancer 1989; 64: 667-672.
35. Oshimi K, Oshimi Y, Akutsu M, et al. Cytotoxicity of interleukin-2-activated lymphocytes for leukemia and lymphoma cells. Blood 1986; 68: 938-948
36. Colleselli P, Rossetti F, Messina C. Autologous bone marrow transplantation for childhood acute lymphoblastic leukemia in remission: first choice for isolated extramedullary relapse. Bone Marrow Transplant 1994; 14: 821-825.
37. Ganem G, Kuentz M, Bemaudin F et al. Central nervous system relapses after bone marrow transplantation for acute lymphoblastic leukemia in remission. Cancer 1989; 64: 1796-1804.
38. Foà R, Fierro MT, Tosti S et al. Induction and persistence of complete remission in a resistant acute myeloid leukemia patient after treatment with recombinant interleukin-2. Leuk Lymphoma 1990; 1: 113-117.